Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

Edwards Lifesciences Corporation (NYSE:EW) ranks among the best medical device stocks to invest in. Piper Sandler maintained ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

Edwards Lifesciences (NYSE: EW) today shared new data demonstrating successful outcomes with its mitral and tricuspid ...

Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.

In conversation with Dr. Shailender Swaminathan, Director, Sapien Labs Centre for Human Brain and Mind at Krea University As the global mental health crisis deepens, Sapien Labs is fast becoming the ...